MedPath

Modeling the Neurological Basis and Characterizing the Neurological Phenotype of Obesity Using Human Neural Stem Cells

Terminated
Conditions
Obesity, Morbid
Interventions
Procedure: Bariatric Surgery
Drug: Anti Obesity Drugs
Registration Number
NCT03263390
Lead Sponsor
University of California, San Diego
Brief Summary

This study aims to characterize the neurological basis of obesity and response to surgical and medical treatment by inducing adult pluripotent stem cells into neuronal cells from subjects that have demonstrated extreme response to bariatric surgery or pharmacological treatment for obesity.

Detailed Description

The investigators will consent subjects who have achieved extreme response to either bariatric surgery or pharmacologic treatment for obesity and harvest fibroblasts from skin biopsies, which will be reprogrammed to induced pluripotent stem cells (iPSC). These iPSC's will then be differentiated into neural progenitor cells, neurons, astrocytes, and microglia to identify genetic and epigenetic pathways altered in disease-specific neural progenitor cells of the brain.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
6
Inclusion Criteria
  • History of obesity
  • Treatment with bariatric surgery
  • Treatment with anti obesity medications
  • Greater than 70% excess weight loss at least 6 months after surgery
  • Greater than 15% weight loss on anti obesity medications
Exclusion Criteria
  • Active cancer, not including non-melanoma skin cancer
  • Active eating disorder
  • Use of anti obesity medications in subjects with a history of bariatric surgery
  • Active complication of the upper GI tract in patients with a history of bariatric surgery

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Bariatric SurgeryBariatric SurgerySubjects that have demonstrated extreme response to bariatric surgery.
Anti Obesity MedicationsAnti Obesity DrugsSubjects that have demonstrated extreme response to anti obesity pharmacotherapy.
Primary Outcome Measures
NameTimeMethod
Generate human cell based models of obesity4 months

Fibroblasts will be expanded in culture and then reprogrammed to hiPSCs.

DNA sequencing4 months

Perform DNA sequencing from skin biopsy progenitor cells

Identification of genetic and epigenetic pathways4 months

Identify genetic and epigenetic pathways altered in disease-specific neural progenitor cells, neurons, and non-neuronal cells of the brain

Differentiation to human CNS cells4 months

Disease specific hiPSCs cells will be differentiated into neural progenitor cells, neurons, astrocytes, and microglia

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University of California San Diego

🇺🇸

La Jolla, California, United States

© Copyright 2025. All Rights Reserved by MedPath